TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21584942

Group type: EXPERIMENTAL
Intervention: tofacitinib 1 mg twice a day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: tofacitinib 3 mg twice a day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice a day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice a day
Number of subjects: 140

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 140
Study: 19673652

Group type: EXPERIMENTAL
Intervention: Cell culture-derived influenza vaccine (CCIV)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Egg-based trivalent inactivated influenza vaccine (TIV)
Number of subjects: 613
Study: 16328852

Group type: EXPERIMENTAL
Intervention: Tiger II catheter (5F)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Judkins catheter (5F R4, L4)
Number of subjects: 160
Study: 12833014

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.3%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 90
Study: 10827213

Group type: EXPERIMENTAL
Intervention: High fruit and vegetable diet (500g daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low fruit and vegetable diet (100g daily)
Number of subjects: 47
Study: 8893577

Group type: EXPERIMENTAL
Intervention: 99mTc-labeled monoclonal granulocyte antibody scintigraphy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 99mTc-labeled monoclonal granulocyte antibody scintigraphy combined with tomographic scan
Number of subjects: 29
Study: 1671468

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide and oral prednisone (n = 55)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Daily oral cyclophosphamide, alternate day prednisone (22 weeks), and weekly plasma exchange (20 weeks) (n = 57)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo medications and sham plasma exchange (n = 56)
Number of subjects: 168
Study: 6839914

Group type: EXPERIMENTAL
Intervention: High fluid regimen (172 +/- 25 ml/kg/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Low fluid regimen (121 +/- 13 ml/kg/day)
Number of subjects: 73
Study: 31533539

Group type: EXPERIMENTAL
Intervention: Cabotegravir LA + rilpivirine LA once every 4 weeks
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Cabotegravir LA + rilpivirine LA once every 8 weeks
Number of subjects: 286

Group type: COMPARATOR
Intervention: Oral maintenance group
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Cabotegravir LA + rilpivirine LA (both 4-week and 8-week groups)
Number of subjects: 286
Study: 29222227

Group type: EXPERIMENTAL
Intervention: m-Health technology-enabled, nurse-guided intervention (n=30) with Blue-toothed UA-767Plus BT BP device and smartphone for monitoring BP for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard of care (n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: m-Health technology-enabled, nurse-guided intervention (n=30)
Number of subjects: 60
Study: 27487543

Group type: EXPERIMENTAL
Intervention: Removable orthodontic appliances of own design and additional application of own theoretical and practical developments (Group 1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Traditional removable appliances with screws (Group 2)
Number of subjects: 37
Study: 24977716

Group type: EXPERIMENTAL
Intervention: Atomoxetine (80-100 mg/d)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study: 22067667

Group type: EXPERIMENTAL
Intervention: rilpivirine
Number of subjects: 1368

Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 1368
Study: 19010983

Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 66

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study: 17985809

Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy (MABT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 14
Study: 15764277

Group type: EXPERIMENTAL
Intervention: Topical steroid (betamethasone), applied twice daily for 4 weeks
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Topical steroid (betamethasone) after 4 weeks for non-responders
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Follow-up after 18 months
Number of subjects: 137
Study: 12475833

Group type: EXPERIMENTAL
Intervention: HFA‐BDP, 80 micro g/d
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: HFA‐BDP, 160 micro g/d
Number of subjects: 353

Group type: COMPARATOR
Intervention: HFA‐placebo
Number of subjects: 353
Study: 10101704

Group type: EXPERIMENTAL
Intervention: Tooth-cleaning technique using a toothbrush without paste (dry brushing)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Tooth-cleaning technique using a brush attached to a rotary instrument with fluoridated prophy paste
Number of subjects: 74
Study: 7921214

Group type: EXPERIMENTAL
Intervention: Cetrorelix (SB-75) 300 micrograms sc
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetrorelix (SB-75) 75, 150, 300, 600, and 1200 micrograms (im, sc, iv)
Number of subjects: 0
Study: 3401697

Group type: EXPERIMENTAL
Intervention: DS (word recognition and decoding skills training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OWLS (oral and written language training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classroom survival skills (alternative treatment control)
Number of subjects: 0
Study: 30625189

Group type: EXPERIMENTAL
Intervention: Combination treatment (BCP + B. infantis)
Number of subjects: 8

Group type: COMPARATOR
Intervention: BCP alone
Number of subjects: 8
Study: 27837387

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (≤3 doses of 100,000 IU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group) with maintenance dose (3420 IU/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (loading dose)
Number of subjects: 50
Study: 26298226

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 126
Study: 23424159

Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN β‐1a 30 μg intramuscularly weekly + glatiramer acetate 20 mg daily)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg daily
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN + GA)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Interferon β‐1a (IFN)
Number of subjects: 1008
Study: 21955196

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ramelteon 32 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ramelteon (all doses)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ramelteon (up to 8 mg)
Number of subjects: 65
Study: 19203773

Group type: EXPERIMENTAL
Intervention: Free iron/folic acid tablets (IFA)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Routine prenatal visits with prescriptions to purchase IFA
Number of subjects: 221
Study: 17372318

Group type: COMPARATOR
Intervention: Control (0 MJ energy)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low-energy (1.5 MJ)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High-energy (3.0 MJ)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: CSP consumption (general)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: CSP composition (fat content)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: CSP consumption frequency
Number of subjects: 72
Study: 15080362

Group type: EXPERIMENTAL
Intervention: Packable composite resin (PCR) - Filtek P60 with Single Bond; mean bond strength 14.8 MPa ± 5.36
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RMGIC) - Fuji II LC; mean bond strength 12.01 MPa ± 4.43
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cavity Conditioner applied to RMGIC; mean bond strength 11.94 MPa ± 4.60
Number of subjects: 0
Study: 11695069

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 370

Group type: COMPARATOR
Intervention: Naproxen 250 mg morning, 500 mg evening
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 370

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 370
Study: 9137848

Group type: EXPERIMENTAL
Intervention: Lamotrigine (200 mg/day, with slow dose-escalation starting at 25 mg/day for 2 weeks, then 50 mg/day for 2 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 77
Study: 7899583

Group type: EXPERIMENTAL
Intervention: High-dose 1‐alpha‐OHD3 plus 24,25(OH)2D3 (2 x 5 micrograms/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monotherapy with 1‐alpha‐OHD3
Number of subjects: 20
Study: 3035960

Group type: EXPERIMENTAL
Intervention: Topical application of fenoterol (50 micrograms, 2 puffs, 4 times a day for 2.5 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 2198436

Group type: EXPERIMENTAL
Intervention: 7 g of olestra twice a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Butter
Number of subjects: 20
Study: 30134777

Group type: EXPERIMENTAL
Intervention: Telecoach-assisted exercise (TAE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Self-regulated exercise (SRE)
Number of subjects: 20
Study: 29641357

Group type: EXPERIMENTAL
Intervention: PACE Plus
Number of subjects: 867

Group type: COMPARATOR
Intervention: PACE
Number of subjects: 867

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 867
Study: 28017423

Group type: EXPERIMENTAL
Intervention: Virtual reality proficiency-based training on a virtual reality simulator (EyeSi) until a proficiency-based test was passed
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 18
Study: 26044291

Group type: EXPERIMENTAL
Intervention: Oral Tenofovir Disoproxil Fumarate (TDF)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Vaginal Tenofovir (TFV) gel
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (oral or vaginal)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 64
Study: 23704191

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (3 μg kg(‐1)) plus wound infiltration with 30 ml of 0.25% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wound infiltration with 3 μg kg(‐1) clonidine plus 30 ml of 0.25% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (wound infiltration with 30 ml of 0.25% bupivacaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (3 μg kg(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wound infiltration with 3 μg kg(‐1) clonidine
Number of subjects: 60
Study: 21056535

Group type: EXPERIMENTAL
Intervention: Readaptation of the dorsolateral peritoneal layer (Group A, n=100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No readaptation of the peritoneal layer (Group B, n=100)
Number of subjects: 200
Study: 19670955

Group type: EXPERIMENTAL
Intervention: Coordinated care management intervention
Number of subjects: 408

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 408
Study: 17200793

Group type: EXPERIMENTAL
Intervention: Individual Psychodynamic Psychotherapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Family Therapy
Number of subjects: 72
Study: 15161773

Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5 mg/meal, maximum dose 4 mg/meal)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nateglinide (60 mg/meal, maximum dose 120 mg/meal)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nateglinide
Number of subjects: 150
Study: 11762413

Group type: EXPERIMENTAL
Intervention: DAB389lL2 (Ontak) - a growth factor fusion toxin containing human interleukin-2 and diphtheria toxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti‐Tac(Fv)‐PE38 (LMB‐2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RFB4(dsFv)‐PE38 (BL22)
Number of subjects: 0
Study: 9628297

Group type: EXPERIMENTAL
Intervention: Curosurf (animal surfactant)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exosurf (artificial surfactant)
Number of subjects: 20
Study: 7892952

Group type: EXPERIMENTAL
Intervention: Patients with tubal pyoinflammatory diseases
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with persistent tubal inflammation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with chronic suppurative process
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 3364800

Group type: COMPARATOR
Intervention: Adrenaline infusion (AI) after placebo (Pl) pretreatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adrenaline infusion (AI) after diltiazem (D) pretreatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adrenaline infusion (AI) after verapamil (V) pretreatment
Number of subjects: 20
Study: 27046339

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CQ10)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: CQ10 + Trimetazidine
Number of subjects: 124
Study: 24612148

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily for 12 weeks
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 12 weeks
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study: 23023841

Group type: EXPERIMENTAL
Intervention: Pharmacist-assisted intervention
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 21177180

Group type: EXPERIMENTAL
Intervention: Cisatracurium infusion with continuous monitoring of T1, adjusted according to muscle relaxation monitoring.
Number of subjects: 60
Study: 18484074

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 64
Study: 16141274

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study: 15380170

Group type: EXPERIMENTAL
Intervention: Patient Information Leaflet (PIL)
Number of subjects: 995

Group type: COMPARATOR
Intervention: Control group (no PIL)
Number of subjects: 995
Study: 10360582

Group type: EXPERIMENTAL
Intervention: Immunosuppression with prednisone (n=22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Immunosuppression without prednisone (n=23)
Number of subjects: 45
Study: 8597678

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen 625 micrograms daily alone
Number of subjects: 321

Group type: COMPARATOR
Intervention: Conjugated equine oestrogen 625 micrograms daily plus norgestrel 150 micrograms daily for the last 12 days of the 'cycle'
Number of subjects: 321
Study: 1767903

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl combined with lignocaine 1.5% with adrenaline 1:200,000
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lignocaine alone
Number of subjects: 200
Study: 6760961

Group type: EXPERIMENTAL
Intervention: Weekly BCG and leukemia cell vaccine (group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Monthly BCG and leukemia cell vaccine (group 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Monthly BCG with no leukemia cell vaccine (group 3)
Number of subjects: 48
Study: 31233281

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg monotherapy
Number of subjects: 423

Group type: COMPARATOR
Intervention: Baricitinib 4 mg plus MTX
Number of subjects: 423

Group type: COMPARATOR
Intervention: MTX added to baricitinib
Number of subjects: 423
Study: 29914954

Group type: EXPERIMENTAL
Intervention: LR-BAC (Low dose rabeprazole 10 mg b.i.d. + bismuth + amoxicillin + clarithromycin)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: LR-BAT (Low dose rabeprazole 10 mg b.i.d. + bismuth + amoxicillin + tetracycline)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: HR-BAC (High dose rabeprazole 20 mg b.i.d. + bismuth + amoxicillin + clarithromycin)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: HR-BAT (High dose rabeprazole 20 mg b.i.d. + bismuth + amoxicillin + tetracycline)
Number of subjects: 431
Study: 26900776

Group type: EXPERIMENTAL
Intervention: NIDCAP
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 43
Study: 25396417

Group type: EXPERIMENTAL
Intervention: CPS-MQ (mefloquine prophylaxis)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CPS-CQ (chloroquine prophylaxis)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (mefloquine prophylaxis with uninfected mosquitoes)
Number of subjects: 15
Study: 23244208

Group type: EXPERIMENTAL
Intervention: Cocculine (homeopathic remedy)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 21177506

Group type: EXPERIMENTAL
Intervention: Iron/Folic Acid
Number of subjects: 676

Group type: COMPARATOR
Intervention: Control (Vitamin A)
Number of subjects: 676
Study: 17581267

Group type: EXPERIMENTAL
Intervention: Guidewire cannulation technique (group II)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional cannulation technique (group I)
Number of subjects: 300
Study: 15803051

Group type: EXPERIMENTAL
Intervention: Antibiotics plus IVIG (Pentaglobin; 7 mL/kg/day for 5 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Antibiotics plus 5% human albumin (control group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: IVIG group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (5% human albumin)
Number of subjects: 56
Study: 12455736

Group type: EXPERIMENTAL
Intervention: FRC[O2]
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: FRC[O2] during mechanical ventilation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Repeated FRC[O2] measurements
Number of subjects: 37
Study: 9594050

Group type: EXPERIMENTAL
Intervention: Intralipid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 7875477

Group type: EXPERIMENTAL
Intervention: Correctol (yellow phenolphthalein)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Correctol (yellow phenolphthalein) with resin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium sulfate
Number of subjects: 12
Study: 2218657

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE), 30 mg/kg/day
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Cefaclor (CEC), 40 mg/kg/day
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate potassium (AMX-CL), 40 mg/kg/day
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate potassium (AMX-CL)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Cefaclor (CEC)
Number of subjects: 377
Study: 348125

Group type: EXPERIMENTAL
Intervention: Low sodium glucose electrolyte solution (sodium concentration of 50 mmol/l)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard oral solution (sodium concentration of 90 mmol/l)
Number of subjects: 39
Study: 30651407

Group type: EXPERIMENTAL
Intervention: Flexible lumbar supports
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo intervention (kinesiotape placed on the low back)
Number of subjects: 28
Study: 28582812

Group type: EXPERIMENTAL
Intervention: Buckwheat products
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal gluten-free diet (Control)
Number of subjects: 19
Study: 26124576

Group type: EXPERIMENTAL
Intervention: Laser pulpotomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Electrosurgery (ES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ferric sulfate (FS)
Number of subjects: 30
Study: 23281658

Group type: EXPERIMENTAL
Intervention: Ramosetron 6 μg·kg(‐1)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Ondansetron 100 μg·kg(‐1)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Both groups received intravenous patient-controlled analgesia with fentanyl
Number of subjects: 218
Study: 22106196

Group type: EXPERIMENTAL
Intervention: Microcyn Rx alone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Oral levofloxacin plus normal saline wound irrigation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin plus Microcyn Rx wound irrigation
Number of subjects: 67
Study: 19491911

Group type: EXPERIMENTAL
Intervention: Riquent (abetimus sodium)
Number of subjects: 0
Study: 17585038

Group type: EXPERIMENTAL
Intervention: 25 g/d of FS
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 50 g/d of FS
Number of subjects: 44

Group type: COMPARATOR
Intervention: 72 g/d of CSB
Number of subjects: 44
Study: 15482245

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (1 MHz, 1.0 W/cm², pulse 1:4, 15 min/session)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low level laser therapy (9 joules, 830 nm infrared laser at five points)
Number of subjects: 50
Study: 11136956

Group type: EXPERIMENTAL
Intervention: Vapreotide (50-microg intravenous bolus followed by an infusion at a rate of 50 microg per hour for five days)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Vapreotide
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Vapreotide and endoscopic treatment
Number of subjects: 196

Group type: COMPARATOR
Intervention: Endoscopic treatment alone
Number of subjects: 196
Study: 9489274

Group type: EXPERIMENTAL
Intervention: EMDR (n = 9)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Exposure in vivo (n = 9)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Computerized exposure (control, n = 8)
Number of subjects: 26
Study: 8852779

Group type: EXPERIMENTAL
Intervention: self-adhesive breast forms
Number of subjects: 67

Group type: COMPARATOR
Intervention: customary breast forms
Number of subjects: 67
Study: 2257060

Group type: EXPERIMENTAL
Intervention: Sinemet CR
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard Sinemet (STD)
Number of subjects: 35
Study: 7018328

Group type: EXPERIMENTAL
Intervention: Intervention group (senior physician spent extra time discussing assessment and management, bypassed clerical procedures, promised continuity of care)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (usual treatment by emergency department nurses and residents)
Number of subjects: 89
Study: 31530666

Group type: EXPERIMENTAL
Intervention: Oral Semaglutide 14 mg
Number of subjects: 822

Group type: COMPARATOR
Intervention: Empagliflozin 25 mg
Number of subjects: 822